Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
FDA establishment 3005693151, Haverhill, Massachusetts, United States. Part of N-Molecular Inc. d.b.a. SOFIE's FDA records. Every inspection FDA has posted for the site, with its outcome and cited regulations.
Inspections: 5
Official action indicated: 1
Warning letters: 2
Inspections by fiscal year
FY2018 to FY2027 to date; 1 classified OAI
How to read this
A hatched bar is a year that is not over, so its count covers only part of the year.
21 CFR 212.50(c)(8). Testing results Your batch production record did not include testing results.
21 CFR 212.30(c). Contact surfaces Your equipment is not maintained so that surfaces that contact components, in-process materials and PET drugs are not reactive, additive, or absorptive so as to alter the quality of the PET drugs.
21 CFR 212.20(e). Written QA procedures established, followed You did not follow written quality assurance procedures.
Voluntary Action Indicated (VAI)
May 16, 2019
Drugs · Drug Quality Assurance
2 cited references
21 CFR 212.20(e). Written QA procedures established, followed You did not follow written quality assurance procedures.
21 CFR 212.60(e). Equipment All equipment used to perform the testing is not suitable for its intended purposes.
Voluntary Action Indicated (VAI)
Feb 28, 2018
Drugs · Drug Quality Assurance
6 cited references
21 CFR 212.30(a). Prevention of contamination Your facilities are not adequate to ensure the prevention of contamination of equipment and product by environmental conditions that could reasonably be expected to have an adverse effect on product quality.
21 CFR 212.50. Adequate controls (general) Your firm lacks adequate production and process controls to ensure the consistent production of a PET drug that meets the applicable standards of identity, strength, quality and purity.
21 CFR 212.20(e). Written QA procedures established, followed You did not follow written quality assurance procedures.
21 CFR 212.30(b). Equipment procedures overall You did not implement procedures to ensure that all your equipment is maintained.
21 CFR 212.30(b). Equipment not suitable You did not implement procedures to ensure that all your equipment is suitable for its intended purposes.
21 CFR 212.30(b). Equipment not clean You did not implement procedures to ensure that all your equipment is clean.
Official Action Indicated (OAI)
Aug 7, 2015
Drugs · Drug Quality Assurance
None posted
Voluntary Action Indicated (VAI)
Dec 11, 2013
Drugs · Drug Quality Assurance
None posted
Voluntary Action Indicated (VAI)
Warning letters
Letters naming this establishment; each opens the letter
An FEI (FDA Establishment Identifier) names one physical site. Inspections, outcomes and citations come from FDA's Data Dashboard; FDA posts citations only for some inspections. Recalls come from FDA's enforcement reports (iRES), one row per recall even when it covers many lots. A contract site can make products for many companies, so the company shown is the one FDA lists as the site's firm. Form 483 observations are read by Arca from the 483s FDA posts in its FOIA reading room, most of them scans: the first sentence of each observation, with redactions as FDA made them. FDA posts 483s for a minority of inspections.FDA Data Dashboard, warning letters and enforcement reports